BTS Appointed Exclusive Global A2P SMS Aggregator for BBIX and SoftBank Corp.
20.1.2025 07:00:00 CET | Business Wire | Press release
Business Telecommunications Services, Inc. (BTS), a leading provider, technology enabler, and trusted partner to CommTech players, has today announced its appointment as the exclusive international A2P SMS aggregator for BBIX, Inc. (BBIX), a wholly-owned subsidiary and the official international A2P SMS gateway of SoftBank Corp. (SoftBank). This agreement marks a significant milestone in the five-year partnership between BTS, BBIX, and SoftBank, enabling seamless and innovative international communication solutions.
As the exclusive aggregator, BTS will be the official channel for terminating international A2P SMS traffic to the SoftBank network. This partnership mandates all communications providers to route their traffic destined for SoftBank through BTS, ensuring seamless and secure delivery. By leveraging the complementary strengths of each company, this partnership enhances the global messaging ecosystem with improved operational efficiencies, enabling a better customer experience and more responsive customer support.
BTS's extensive global footprint and BBIX's market expertise will help partners navigate complex regulatory environments, expand market reach, and unlock cross-selling opportunities that can drive higher revenue growth. The partnership also ensures the delivery of secure and reliable messaging services by leveraging BTS’s advanced S1 Platform.
“As a trusted partner, we are pleased to expand our collaboration with BTS to ensure the seamless aggregation of global A2P SMS traffic,” said Hideyuki Sasaki, President & CEO of BBIX. “By combining our strengths and complementary expertise, we are delivering a secure and reliable solution that enhances the SoftBank network and supports the evolving needs of our global partners.”
“As a trusted partner and joint venture collaborator, BTS has consistently demonstrated the capabilities and expertise we need to support SoftBank’s global communications strategy,” commented Norioki Sekiguchi, Vice President of SoftBank Corp.’s Global Business Division. “By leveraging BBIX as our official gateway, BTS will ensure the seamless and secure aggregation of international A2P SMS traffic to our network, enabling us to deliver greater reliability and performance for our customers worldwide.”
This agreement solidifies BTS’s leadership in the global messaging space and underscores the ongoing collaboration between BTS, BBIX, and SoftBank. Together, they continue to pioneer innovative and scalable solutions that address the dynamic needs of the global communications industry.
“Becoming the exclusive aggregator of A2P SMS for BBIX and SoftBank marks an important milestone in our partnership, which began over five years ago,” concluded Andrés Proaño, EVP & CRO of BTS. “This collaboration reflects the strength of our relationship and our shared commitment to driving innovation in global communications. With many more strategic initiatives ahead, such as Open Connectivity eXchange (OCX), Roaming Peering eXchange (RPX), and advanced AI solutions, this agreement is a key step forward in a partnership poised for even greater growth and success.”
About BTS
BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform and an international network of 400+ direct partners, BTS delivers advanced AI-driven solutions specializing in voice, messaging, cloud communications, and innovative services that drive growth for MNOs, carriers, digital players, and hyperscalers. BTS powers 18+ billion voice minutes annually across 180+ countries, with extensive cloud telephony coverage in 90+ hard-to-reach markets and global reach for messaging services.
About BBIX
BBIX was established in 2003 to be a carrier-free internet exchange (IX) provider headquartered in Japan and serving Asia, Europe, and the US. It provides various connectivity services such as IX, Roaming Peering eXchange (RPX), Open Connectivity eXchange (OCX), as well as A2P SMS solutions. BBIX has established itself as one of the leading IXs in Asia, with a growing membership and an expanding global footprint.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250119536400/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom